Efficacy and safety of natalizumab in crohn's disease patients treated at 6 boston academic hospitals

Inflammatory Bowel Diseases

Volumn 19, Issue 11, 2013, Pages 2457-2463

  Juillerat, Pascal ^a,b   Wasan, Sharmeel K ^c   Fowler, Sharyle A ^a   Friedman, Sonia ^d   Pabby, Vikas K ^d   Coukas, Jennifer A ^c   Barto, Amy E ^e   Pellish, Randall ^f   Germansky, Katharine A ^g   Cheifetz, Adam S ^g   Korzenik, Joshua R ^a,b,c   Farraye, Francis A ^c   Yajnik, Vijay ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^f UNIVERSITY OF MASSACHUSETTS   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Clinical practice; Crohn's disease; Efficacy; Inflammatory bowel disease; Natalizumab; Safety

Indexed keywords

ANTIBIOTIC AGENT; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL ABSCESS; ADULT; ANUS DISEASE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HERPES ZOSTER; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BOSTON; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTEGRIN ALPHA4; MALE; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SAFETY;

EID: 84888271656     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182a32a0d     Document Type: Article

References (20)

1. Baumgart DC, Sandborn WJ. Crohns disease. Lancet. 2012;380: 1590-1605.
2. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohns disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-96.
3. National Multiple Sclerosis Society Web site (USA) Available at www.nationalmsssociety.org. Accessed January 7, 2013.
4. Harvey RF, Bradshaw JM. A simple index of Crohns-disease activity. Lancet. 1980;1:514.
5. Harvey RF, Bradshaw MJ. Measuring Crohns disease activity. Lancet. 1980;1:1134-1135.
6. Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohns disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007; 13:2-11.
7. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebocontrolled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohns disease. Gastroenterology. 2001;121:268-274.
8. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohns disease. N Engl J Med. 2003;348:24-32.
9. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohns disease. N Engl J Med. 2005;353: 1912-1925.
10. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohns disease activity index. National Cooperative Crohns Disease Study. Gastroenterology. 1976;70:439-444.
11. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohns disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672-1683.
12. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohns disease. N Engl J Med. 2005;353:362-368.
13. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924-933.
14. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438-446.
15. Kane SV, Horst S, Sandborn WJ, et al. Natalizumab for moderate to severe Crohns disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012;18:2203-2208.
16. Sakuraba A, Keyashian K, Correia C, et al. Natalizumab in Crohns disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013;19:621-626.
17. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumabassociated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870-1880.
18. Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70:742-750.
19. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol. 2010;68:295-303.
20. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012;78:1736-1742.